News & Events
November 7, 2023
C-Path’s T1D Consortium New-onset Article Published in The Lancet Diabetes and EndocrinologyResearch confirms immune-based therapies improve outcomes in new-onset T1D TUCSON, Ariz., November 7, 2023 — Critical Path Institute’s (C-Path) Type 1 Diabetes Consortium, along with external collaborators from Cardiff University and the University of Alberta, today announced the publishing of “C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes”......
October 25, 2023
C-Path Announces Significant Expansion in Neonatal RWD ProjectDetails of the expansion will be a highlight of the Institute’s Scientific Breakthrough Summit Oct. 26-27 in D.C. TUCSON, Ariz., October 25, 2023 — Critical Path Institute’s (C-Path) International Neonatal Consortium (INC) and the Institute for Advanced Clinical Trials for Children (I-ACT) are thrilled to announce a significant expansion of neonatal data in their Real-World......
August 17, 2023
C-Path to Host a Scientific Breakthrough Summit Oct. 26-27Addressing Unmet Regulatory Needs and Drug Development Opportunities through Collaborations in Type 1 Diabetes, Alpha-1 Antitrypsin Deficiency, Lysosomal Disorders, and Vulnerable Populations including Neonates TUCSON, Ariz., Aug. 17, 2023 – Critical Path Institute (C-Path), a leading nonprofit dedicated to accelerating drug development to advance better treatments for people worldwide, is pleased to announce its upcoming......
August 9, 2023
C-Path Welcomes Sanofi to its Type 1 Diabetes Consortium to Help Advance Drug Development
C-Path announced today that Sanofi, a global leader in immunology and diabetes care, has joined its Type 1 Diabetes Consortium (T1DC). Sanofi joins T1DC as part of its commitment to push the boundaries of innovation to improve the lives of those with diabetes.
July 18, 2023
C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships
C-Path ts activity in Europe and broaden its global operations. C-Path operates in Europe as a nonprofit organisation that builds consensus among its stakeholders from around the world to improve public health. The organisation shares expertise, data, risks and costs to move regulatory science forward.